Please login to the form below

Not currently logged in
Email:
Password:

Bristol Myers Squibb

This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Amgen strikes $240m autoimmune deal with Evoq Therapeutics

Amgen’s autoimmune franchise includes psoriasis blockbuster Otezla (apremilast), which it picked up from Celgene after it merged with Bristol Myers Squibb in 2019.

Latest news

More from news
Approximately 165 fully matching, plus 918 partially matching documents found.

Latest Intelligence

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce

  • The impact of COVID-19 on clinical trials The impact of COVID-19 on clinical trials

    Eli Lilly, Bristol-Myers Squibb and Pfizer also have multiple development programmes that are paused or delayed.

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    2. Ozanimod, developed by Bristol-Myers Squibb, is an orally delivered agonist of sphingosine-1- phosphate type 1 (S1P1) and S1P5 receptors, two proteins with a pivotal role in the trafficking ... 11. Liso-cel for large B-cell lymphoma is being developed

  • Pharma funding and M&A in 2020 Pharma funding and M&A in 2020

    Indeed, 2019 was notable for Bristol-Myers Squibb’s acquisition of Celgene (which at a stroke bolstered its immunotherapy and oncology departments), as well as AbbVie’s acquisition of Allergan for

More from intelligence
Approximately 4 fully matching, plus 47 partially matching documents found.

Latest appointments

More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics